DISCOVERIES AND INNOVATIONS

Diaceutics Report Highlights Persistent Gaps in Precision Medicine for Lung Cancer Patients
New research from Diaceutics found that 65% of eligible patients with advanced non-small cell lung cancer (aNSCLC) in the US are still not receiving the most appropriate targeted therapies, despite significant improvements in biomarker testing. Drawing on realworld data from more than 35,800 newly diagnosed patients between 2019 and 2023, the report shows that overall patient loss across the precision medicine pathway has remained largely unchanged, with 65.1% of patients missing optimal treatment opportunities in 2023 compared with 64.4% in 2019.

New research from Diaceutics found that 65% of eligible patients with aNSCLC in the US are still not receiving the most appropriate targeted therapies.

While diagnostic testing performance has improved, the study found that the greatest patient loss now occurs at the treatment decision stage, where missed opportunities increased from 29.2% to 43.3%. According to the analysis, many oncologists continue to make treatment decisions before receiving complete biomarker results, and more than half do not consistently act on biomarker report recommendations. The findings suggest that the primary challenge in precision medicine has shifted from testing access to ensuring diagnostic insights are effectively translated into treatment decisions, underscoring the need for better clinical support and more integrated, datadriven care pathways.

Innovent Showcases Next-Generation Obesity and Metabolic Disease Pipeline at ADA 2026
Innovent Biologics presented new clinical and preclinical data from its obesity and metabolic disease portfolio at the 2026 American Diabetes Association Scientific Sessions, highlighting several investigational therapies designed to improve weight management and metabolic health. The company shared Phase 1 and preclinical results for IBI3032, an oral daily GLP-1 receptor agonist that demonstrated encouraging weight-loss efficacy and a manageable safety profile, as well as preclinical data for IBI3042, a potential once-weekly oral GLP-1 therapy. Additional findings showcased IBI3040, a novel amylin analog with promising weight-loss effects, and IBI3046, an INHBE-targeting siRNA therapy that produced substantial reductions in body weight and fat mass in preclinical studies.

The data underscore Innovent’s strategy to build a differentiated obesity and metabolic disease pipeline focused on addressing key treatment challenges such as tolerability, dosing convenience, durability of weight loss, and preservation of lean body mass. The company also highlighted ongoing development of mazdutide, its dual GCG/GLP-1 receptor agonist, alongside its broader portfolio of next-generation therapies aimed at expanding treatment options for patients with obesity, type 2 diabetes, and related metabolic conditions.

 

TRENDSETTING

Sanofi and Owkin Expand Partnership to Deploy AI Agents Across Drug Development Workflows
Sanofi and Owkin have expanded their existing collaboration from oncology-focused target discovery into the development of AI agents designed to operate directly within biopharmaceutical workflows. The agreement centers on deploying AI-driven “biopharma agents” through Owkin’s K Pro platform, which functions as an AI scientist capable of analyzing multimodal patient data, biomarker information, and clinical research inputs to support drug development decisions. The new phase of the partnership reflects a broader shift toward embedding agentic AI systems into core R&D processes rather than using them as standalone tools. These AI agents are intended to assist with tasks such as target identification, patient stratification, biomarker analysis, and clinical trial design, enabling researchers and strategy teams to interact with complex datasets through natural language and improve decision-making across the drug development lifecycle.

THERAPEUTIC TALK

GLP-1 Outcomes, siRNA Funding, and Cancer Drug Approval
Novo Nordisk presented new Phase III FLOW trial data showing that semaglutide (Ozempic) not only reduces major kidney disease events and mortality in patients with type 2 diabetes and chronic kidney disease, but may also improve health-related quality of life. Analysis of more than 3,500 participants found that patients receiving semaglutide experienced stable quality-of-life scores over two years compared with declines in the placebo group, translating to an estimated eight additional healthy days per year.

Novo Nordisk presents trial data showing that Ozempic may improve health-related quality of life.

In parallel developments, OliX Pharmaceuticals raised approximately $71 million to advance its siRNA-based pipeline across dermatology, ophthalmology, and metabolic liver disease, including its lead candidate in metabolicassociated steatohepatitis. Additionally, the UK’s National Institute for Health and Care Excellence recommended reimbursement of AbbVie’s ovarian cancer therapy Elahere for NHS use, marking the first new approved treatment option in over two decades for platinum-resistant disease and expanding access based on demonstrated survival benefits in the MIRASOL study.

FDA UPDATE

Pfizer’s Hympavzi Expands FDA Label to Include Younger Hemophilia Patients
Pfizer has received FDA approval to expand the label for its hemophilia therapy Hympavzi, extending use to patients aged 6 and older with hemophilia A or B, regardless of inhibitor status. The drug was originally approved in 2024 for patients 12 and older without inhibitors, but the updated indication now includes both pediatric and adult patients, including those who develop inhibitor antibodies that can reduce the effectiveness of traditional clotting factor therapies.

Pfizer has received FDA approval to expand the label for its hemophilia therapy Hympavzi to patients aged 6 and older.

Hympavzi is administered weekly via a prefilled, autoinjector pen and is used as a prophylactic treatment to reduce bleeding episodes associated with hemophilia. Clinical trial data showed significant reductions in annualized bleeding rates in both pediatric and adult  populations, including patients with and without inhibitors. Hemophilia affects more than 800,000 people globally, with inhibitor development occurring in a subset of patients and contributing to more severe disease management challenges, particularly in children who are at risk of joint damage from repeated bleeding episodes.

FDA Reviews Safety of Infant RSV Preventive Shots from AstraZeneca, Sanofi, and Merck
The US Food and Drug Administration (FDA) is reviewing the safety of respiratory syncytial virus (RSV) preventive shots used in infants, according to Reuters. The investigation includes products from AstraZeneca, Sanofi, and Merck & Co., including AstraZeneca and Sanofi’s Beyfortus and Merck’s recently endorsed Enflonsia. These therapies are long-acting monoclonal antibodies designed to protect infants under 8 months of age during their first RSV season.

Merck confirmed discussions with the FDA regarding Enflonsia’s safety profile following its June endorsement, emphasizing ongoing scientific dialogue and regulatory review. The scrutiny comes amid broader federal attention on vaccine and immunization policies in the US, including recent changes to advisory recommendations and heightened debate over vaccine safety oversight. Both Beyfortus and Enflonsia remain recommended preventive options for infant RSV protection while regulatory review continues.